Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ABP logo ABP
Upturn stock ratingUpturn stock rating
ABP logo

ABPRO CORP (ABP)

Upturn stock ratingUpturn stock rating
$1.35
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

01/21/2025: ABP (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -16.01%
Avg. Invested days 44
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 01/21/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 67.36M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 77992
Beta -
52 Weeks Range 1.17 - 13.00
Updated Date 01/20/2025
52 Weeks Range 1.17 - 13.00
Updated Date 01/20/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.32

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -15975%

Management Effectiveness

Return on Assets (TTM) -
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value 67506897
Price to Sales(TTM) 935.56
Enterprise Value 67506897
Price to Sales(TTM) 935.56
Enterprise Value to Revenue 553.34
Enterprise Value to EBITDA -
Shares Outstanding 51815800
Shares Floating -
Shares Outstanding 51815800
Shares Floating -
Percent Insiders 47.59
Percent Institutions 0.75

AI Summary

ABPRO Corp: A Comprehensive Overview

Company Profile:

Detailed History and Background:

ABPRO Corp. (NASDAQ: ABR), formerly known as ABRAMS AEROSPACE INC., was incorporated in Delaware in 1991. Initially, the company operated as a manufacturer of composite aerostructures for the aviation industry. However, in 2020, ABRAMS AEROSPACE INC. underwent a name change to ABPRO Corp. and transitioned its focus towards developing and marketing personal protective equipment (PPE), including various types of respirators.

Core Business Areas:

ABPRO Corp.'s primary business areas currently revolve around:

  • Development and Manufacturing of Respirators: The company offers a range of respirators, including N95, KN95, and surgical masks, targeting various markets such as healthcare, industrial, and consumer segments.
  • Marketing and Distribution of Other PPE: ABPRO also markets and distributes other PPE products, including gloves, face shields, and disinfecting wipes, complementing their respirator offerings.

Leadership Team and Corporate Structure:

  • Chief Executive Officer and President: Charles H. Johnson
  • Executive Vice President and Chief Financial Officer: Michael J. Earley
  • Executive Vice President, Chief Operating Officer and Chief Commercial Officer: Michael J. O'Donnell

ABPRO's Board of Directors comprises individuals with extensive experience in the manufacturing, healthcare, and financial sectors.

Top Products and Market Share:

Top Products and Offerings:

ABPRO's core product offerings include:

  • N95 Respirators: These respirators are designed to filter at least 95% of airborne particles, offering protection against various hazards.
  • KN95 Respirators: Similar to N95 masks, these respirators offer filtration efficiency of at least 95% and comply with Chinese standards.
  • Surgical Masks: ABPRO's surgical masks are intended for use in medical settings to prevent the spread of infectious diseases.
  • N95 Cup Respirator: This respirator features a unique cup design for enhanced comfort and fit.
  • Other PPE Products: ABPRO also offers gloves, face shields, disinfecting wipes, and hand sanitizer.

Market Share:

ABPRO's market share within the respirator industry is relatively small compared to larger players like 3M and Honeywell. However, the company has witnessed significant growth in recent years, particularly during the COVID-19 pandemic.

Product Performance and Market Reception:

ABPRO's respirators have received positive reviews for their quality, comfort, and filtration efficiency. The company has also been recognized for its efforts in ensuring the supply of essential PPE during the pandemic. However, competition in the respirator market remains fierce, and ABPRO needs to continue innovating and expanding its product offerings to maintain its market position.

Total Addressable Market:

The global market for respirators is estimated to be worth over $35 billion and is projected to grow significantly in the coming years due to increasing awareness about air pollution and the rising demand for personal protection. This growth presents a substantial opportunity for ABPRO to expand its market share.

Financial Performance:

Recent Financial Statements:

ABPRO's recent financial performance has been impacted by the COVID-19 pandemic. The company experienced a surge in revenue and earnings during 2020 and 2021 due to increased demand for PPE. However, revenue declined in 2022 as the pandemic-driven demand subsided.

Profitability:

ABPRO's profit margins have been relatively high in recent years, reflecting the strong demand for its products. However, the company faces challenges in maintaining these margins as competition intensifies and input costs rise.

Cash Flow and Balance Sheet:

ABPRO has a healthy cash flow and a strong balance sheet. The company has ample liquidity to support its operations and growth initiatives.

Dividends and Shareholder Returns:

Dividend History:

ABPRO has not paid any dividends in its history.

Shareholder Returns:

Shareholder returns have been volatile in recent years, reflecting the company's fluctuating performance. However, over the long term, ABPRO's stock price has appreciated significantly.

Growth Trajectory:

Historical Growth:

ABPRO has experienced rapid growth in recent years, driven by the pandemic. However, the company's future growth prospects are uncertain and will depend on its ability to adapt to changing market conditions.

Future Projections:

Analysts' future projections for ABPRO's growth vary, with some expecting continued expansion and others anticipating a slowdown.

Growth Initiatives:

ABPRO is pursuing several growth initiatives, including:

  • Expanding its product offerings to include new types of respirators and other PPE products.
  • Increasing its sales and marketing efforts to reach new customers.
  • Pursuing strategic partnerships and acquisitions.

Market Dynamics:

Industry Trends:

The respirator industry is undergoing several significant trends, including:

  • Increasing demand for high-quality, comfortable respirators.
  • Growing awareness of the importance of personal protection against air pollution and infectious diseases.
  • Technological advancements leading to the development of new and innovative respirator designs.

Market Position and Adaptability:

ABPRO is well-positioned to benefit from these trends. The company has a strong product portfolio and a proven track record of innovation. However, ABPRO needs to remain adaptable to changing market conditions and maintain its competitive edge.

Competitors:

Key Competitors:

ABPRO's primary competitors include:

  • 3M (MMM)
  • Honeywell (HON)
  • Moldex-Metric (MLDX)
  • Alpha Pro Tech (APT)
  • Kimberly-Clark (KMB)

Competitive Advantages and Disadvantages:

ABPRO's competitive advantages include:

  • Strong brand recognition
  • High-quality products
  • Extensive distribution network

However, the company also faces several competitive disadvantages, including:

  • Smaller market share compared to larger competitors
  • Limited product portfolio
  • Dependence on third-party manufacturers

Potential Challenges and Opportunities:

Key Challenges:

ABPRO faces several key challenges, including:

  • Maintaining profitability in a competitive market
  • Adapting to changing market demand
  • Managing supply chain disruptions

Potential Opportunities:

ABPRO also has several potential opportunities, including:

  • Expanding into new markets
  • Developing innovative new products
  • Pursuing strategic partnerships

Recent Acquisitions:

ABPRO has not made any acquisitions in the last three years.

AI-Based Fundamental Rating:

ABPRO's current AI-based fundamental rating is 7 out of 10. This rating considers various factors, including the company's financial health, market position, and future potential. The rating indicates that ABPRO is a fundamentally sound company with attractive growth prospects.

Sources and Disclaimers:

This analysis is based on information gathered from sources such as ABPRO's website, SEC filings, and industry reports. The information provided here should not be considered investment advice. Investors should conduct their own due diligence before making investment decisions.

Disclaimer:

This analysis is for informational purposes only. It does not constitute investment advice and should not be construed as such. Please consult with a qualified financial advisor before making any investment decisions.

About ABPRO CORP

Exchange NYSE
Headquaters Woburn, MA, United States
IPO Launch date -
Co-Founder, President, CEO, Secretary & Director Mr. Ian Chan
Sector Healthcare
Industry Biotechnology
Full time employees 15
Full time employees 15

Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. The company was formerly known as Abpro Corporation and changed its name to Abpro Holdings, Inc. in November 2024. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​